- $669.93m
- $346.09m
Aura Biosciences Inc expected to post a loss of 41 cents a share - Earnings Preview
Aura Biosciences Inc expected to post a loss of 41 cents a share - Earnings Preview
Aura Biosciences Inc expected to post a loss of 41 cents a share - Earnings Preview
Aura Biosciences Inc expected to post a loss of 41 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Ameren Corp, Bread Financial Holdings, Exelon Corp
U.S. RESEARCH ROUNDUP- Atlassian Corp, Broadcom, Cerevel Therapeutics Holdings
Brief: Aura Biosciences Q3 Operating Expenses USD 20.488 Million
U.S. RESEARCH ROUNDUP-Air Products and Chemicals, Assurant, Celanese
U.S. STOCKS ON THE MOVE-Zimmer Biomet, Olaplex, Datadog
U.S. STOCKS ON THE MOVE-Uber, Olaplex, Planet Fitness
Auro Biosciences slides on pricing stock offering
Brief: Aura Biosciences Announces Pricing Of Public Offering Of Common Stock
Brief: Aura Biosciences Announces Proposed Public Offering Of Common Stock
Aura Biosciences Inc expected to post a loss of 52 cents a share - Earnings Preview
Brief: Aura Biosciences To Present Updated Phase 2 Data Evaluating Bel-Sar For Early-Stage Choroidal Melanoma At AAO 2023
Aura Biosciences Inc expected to post a loss of 52 cents a share - Earnings Preview
Aura Biosciences Inc reports results for the quarter ended in June - Earnings Summary
Brief: Aura Biosciences Q2 Net Income USD -18.299 Million
Aura Biosciences Inc expected to post a loss of 49 cents a share - Earnings Preview